Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Natalizumab treatment reduces endothelial activity in MS patients.

Alban Millonig,Harald Hegen,Franziska Di Pauli,Rainer Ehling,Claudia Gneiss,Martina Hoelzl,Bettina Künz,Andreas Lutterotti,Dagmar Rudzki,Thomas Berger,Markus Reindl,Florian Deisenhammer

Journal of Neuroimmunology（2010）

Cited 34|Views12
No score
Abstract
Vascular cell adhesion molecule-1 a ligand for leukocyte very late activating antigen-4 is a key player in leukocyte extravasation in MS lesions. Natalizumab a monoclonal antibody against VLA-4 blocks this interaction. VCAM-1 and its soluble form are up-regulated during endothelial activation in MS.
More
Translated text
Key words
Multiple sclerosis,Natalizumab,Vascular cell adhesion molecule-1,Very late activating antigen-4,Neutralizing antibodies,sVCAM
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined